Haisma HJ - Search Results

1

Endosomal escape pathways for delivery of biologicals.

Varkouhi AK, Scholte M, Storm G, Haisma HJ. Varkouhi AK, et al. Among authors: haisma hj. J Control Release. 2011 May 10;151(3):220-8. doi: 10.1016/j.jconrel.2010.11.004. Epub 2010 Nov 13. J Control Release. 2011. PMID: 21078351 Review.

2

Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.

Fonseca MJ, Jagtenberg JC, Haisma HJ, Storm G. Fonseca MJ, et al. Among authors: haisma hj. Pharm Res. 2003 Mar;20(3):423-8. doi: 10.1023/a:1022608321861. Pharm Res. 2003. PMID: 12669963

3

Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.

Fonseca MJ, Storm G, Hennink WE, Gerritsen WR, Haisma HJ. Fonseca MJ, et al. Among authors: haisma hj. J Gene Med. 1999 Nov-Dec;1(6):407-14. doi: 10.1002/(SICI)1521-2254(199911/12)1:6<407::AID-JGM71>3.0.CO;2-Q. J Gene Med. 1999. PMID: 10753066

4

Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.

Vingerhoeds MH, Haisma HJ, Belliot SO, Smit RH, Crommelin DJ, Storm G. Vingerhoeds MH, et al. Among authors: haisma hj. Pharm Res. 1996 Apr;13(4):604-10. doi: 10.1023/a:1016010524510. Pharm Res. 1996. PMID: 8710754

5

Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties.

Fonseca MJ, Haisma HJ, Klaassen S, Vingerhoeds MH, Storm G. Fonseca MJ, et al. Among authors: haisma hj. Biochim Biophys Acta. 1999 Jul 15;1419(2):272-82. doi: 10.1016/s0005-2736(99)00073-5. Biochim Biophys Acta. 1999. PMID: 10407077 Free article.

6

A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs.

Vingerhoeds MH, Haisma HJ, van Muijen M, van de Rijt RB, Crommelin DJ, Storm G. Vingerhoeds MH, et al. Among authors: haisma hj. FEBS Lett. 1993 Dec 28;336(3):485-90. doi: 10.1016/0014-5793(93)80861-n. FEBS Lett. 1993. PMID: 8282116 Free article.

7

Targeted adenovirus mediated inhibition of NF-κB-dependent inflammatory gene expression in endothelial cells in vitro and in vivo.

Kułdo JM, Ásgeirsdóttir SA, Zwiers PJ, Bellu AR, Rots MG, Schalk JA, Ogawara KI, Trautwein C, Banas B, Haisma HJ, Molema G, Kamps JA. Kułdo JM, et al. Among authors: haisma hj. J Control Release. 2013 Feb 28;166(1):57-65. doi: 10.1016/j.jconrel.2012.12.016. Epub 2012 Dec 20. J Control Release. 2013. PMID: 23266453

8

Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors.

Rots MG, Curiel DT, Gerritsen WR, Haisma HJ. Rots MG, et al. Among authors: haisma hj. J Control Release. 2003 Feb 21;87(1-3):159-65. doi: 10.1016/s0168-3659(02)00360-7. J Control Release. 2003. PMID: 12618032 Review.

9

Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter.

Gommans WM, McLaughlin PM, Schalk JA, Groothuis GM, Haisma HJ, Rots MG. Gommans WM, et al. Among authors: haisma hj. J Control Release. 2007 Jan 22;117(1):1-10. doi: 10.1016/j.jconrel.2006.10.006. Epub 2006 Nov 28. J Control Release. 2007. PMID: 17137670

10

Towards a double controlled conditionally replicative adenovirus for potent and specific melanoma cell kill.

Gommans WM, Oosterhuis D, Dmitriev I, Schaack J, Curiel DT, Haisma HJ, Rots MG. Gommans WM, et al. Among authors: haisma hj. J Control Release. 2006 Nov 28;116(2):e64-6. doi: 10.1016/j.jconrel.2006.09.052. J Control Release. 2006. PMID: 17718975 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

151 results

Search Page

Filters